guideline
Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*
Gail Jones,
Nilima Parry-Jones, Bridget Wilkins,
Monica Else,
Daniel Catovsky,
Gail Jones
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Search for more papers by this authorBridget Wilkins
Guys and St Thomas’ NHS Foundation Trust, London
Search for more papers by this authorMonica Else
The Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, UK
Search for more papers by this authorDaniel Catovsky
The Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, UK
Search for more papers by this authorGail Jones,
Nilima Parry-Jones, Bridget Wilkins,
Monica Else,
Daniel Catovsky,
Gail Jones
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Search for more papers by this authorBridget Wilkins
Guys and St Thomas’ NHS Foundation Trust, London
Search for more papers by this authorMonica Else
The Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, UK
Search for more papers by this authorDaniel Catovsky
The Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, UK
Search for more papers by this authorGail Jones, Consultant Haematologist, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Road, Newcastle upon Tyne, NE7 7DN, UK. E-mail: [email protected]
Compiled on Behalf of the Clinical Task Force of the British Committee for Standards in Haematology as a revision to original guideline published February 2000.
Summary
The British Committee for Standards in Haematology first produced guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant in 2000. This revision updates those guidelines and covers the areas of diagnosis, treatment and assessment of response to therapy.
References
- Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1989) The French-American-British (FAB) Cooperative Group, Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. Journal of Clinical Pathology, 42, 567–584.
- Bouroncle, B.A., Wiseman, B.K. & Doan, C.A. (1958) Leukemic reticuloendotheliosis. Blood, 13, 609–630.
- Catovsky, D. (1996) Clinical experience with 2-deoxycoformycin. Hematology and Cell Therapy, 38, S103–S107.
- Catovsky, D.; on behalf of the Clinical Task Force of the British Committee for Standards in Haematology (2000). Hairy cell leukaemia. Guidelines on diagnosis and therapy. http://www.bcshguidelines.com/documents/hairy_cell_leukaemia_2000.pdf
- Catovsky, D., Matutes, E., Talavera, J.G., O’Connor, N.T., Johnson, S.A., Emmett, E., Corbett, L. & Swansbury, J. (1994) Long term results with 2′deoxycoformycin in hairy cell leukaemia. Leukemia and Lymphoma, 14(Suppl. 1), 109–113.
- Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F. & Petrini, M. (2004) Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal of Haematology, 73, 412–417.
- Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F. & Petrini, M. (2008) Rituximab as treatment for minimal residual disease in hairy cell leukaemia extended follow-up. British Journal of Haematology, 143, 296–298.
- Chadha, P., Rademaker, A.W., Mendiratta, P., Kim, B., Evanchuk, D.M., Hakimian, D., Peterson, L.C. & Tallman, M.S. (2005) Treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood, 106, 241–246.
- Chen, Y.H., Tallman, M.S., Goolsby, C. & Peterson, L. (2006) Immunophenotypic variations in hairy cell leukemia. American Journal of Clinical Pathology, 125, 251–259.
- Cheson, B.D., Sorensen, J.M., Vena, D.A., Montello, M.J., Barrett, J.A., Damasio, E., Tallman, M., Annino, L., Connors, J., Coiffier, B. & Lauria, F. (1998) Treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine via the Group C Protocol Mechanism of the National Cancer Institute: a report of 979 patients. Journal of Clinical Oncology, 16, 3007–3015.
- Davies, J.M., Lewis, M.P.N., Wimperis, J., Rafi, I., Ladhani, S. & Bolton-Maggs, P.H.B. (2011) Review of guidelines for the prevention and treatment of infection in patients with an absent of dysfunctional spleen. Prepared on behalf of the British Committee for Standards in Haematology by a Working Party of the Haematooncology Task Force. British Journal of Haematology, 155, 308–317.
-
Dearden, C. &
Catovsky, D. (1990) Treatment of hairy cell leukaemia with 2-deoxycoformycin.
Leukemia and Lymphoma, 1, 179–185.
10.3109/10428199009042478 Google Scholar
- Dearden, C.E., Else, M. & Catovsky, D. (2011) Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leukaemia and Lymphoma, 52(Suppl. 2), 21–24.
- Del Giudice, I., Matutes, E., Morilla, R., Morilla, A., Owusu-Ankomah, K., Rafiq, F., A’Hern, R., Delgado, J., Bazerbashi, M.B. & Catovsky, D. (2004) The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica, 89, 303–308.
- Else, M., Ruchlemer, R., Osuji, N., Del Guidice, I., Matutues, E., Woodman, A., Wotherspoon, A., Swansbury, J., Dearden, C. & Catovsky, D. (2005) Long remissions in hairy cell leukaemia with purine analogues: a report of 219 patients with a median follow-up of 12.5 years. Cancer, 104, 2442–2448.
- Else, M., Osuji, N., Forconi, F., Dearden, C., Del Guidice, I., Matutes, E., Wotherspoon, A., Lauria, F. & Catovsky, D. (2007) The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent. refractory hairy cell leukaemia. Cancer, 110, 2240–2247.
- Else, M., Dearden, C.E., Matutes, E., Garcia-Talavera, J., Ama, Z., Rohatiner, S., Johnson, S.A.N., O’Connor, N.T.J., Haynes, A., Osuji, N., Forconi, F., Lauria, F. & Catovsky, D. (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. British Journal of Haematology, 145, 733–740.
- Else, M., Dearden, C.E., Matutes, E., Forconi, F., Lauria, F., Ahmad, H., Kelly, S., Liyanage, A., Ratnayake, V., Shankan, J., Whalley, I. & Catovsky, D. (2011) Rituximab with pentostatin or cladribine; an effective combination treatment for hairy cell leukaemia after disease recurrence. Leukemia and Lymphoma, 52(Suppl. 2), 75–78.
- Falini, B., Tiacci, E., Liso, A., Basso, K., Sabattini, E., Pacini, R., Foa, R., Pulsoni, A., Dalla Favera, R. & Pileri, S. (2004) Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet, 363, 1869–1870.
- Foucar, K., Falini, B., Catovsky, D. & Stein, H. (2008) Hairy cell leukaemia. In: WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. (ed. by Swerdlow, S.H. Campo, E. Harris, N.L. Jaffe, E.S. Pileri, S.A. Stein, H. Thiele, J. & J.W. Vardiman), pp. 188–190. IARC Press, Lyon.
- Golomb, H.M., Dodge, R., Mick, R., Budman, D., Hutchison, R., Horning, S.J. & Schiffer, C.A. (1994) Pentostatin treatment for hairy cell leukaemia patients who failed initial therapy with recombinant interferon-alpha: a report of CALGB study 8515. Leukemia, 8, 2037–2040.
- Grever, M.R. (2010) How I treat hairy cell leukaemia. Blood, 115, 21–28.
- Grever, M., Kopecky, K., Foucar, M.K., Head, D., Bennett, J.M., Hutchison, R.E., Corbett, W.E., Cassileth, P.A., Habermann, T. & Golomb, H. (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukaemia: an intergroup study. Journal of Clinical Oncology, 13, 974–982.
- Habermann, T.M., Anderson, J.W., Cassileth, P.A., Bennett, J.M. & Oken, M.M. (1992) Sequential administration of recombinant interferon alpha with deoxycoformycin in the treatment of hairy cell leukaemia. British Journal of Haematology, 80, 466–471.
- Hoffman, M.A., Janson, D., Rose, E. & Rai, K.R. (1997) Treatment of hairy cell leukaemia with cladribine: response, toxicity and long-term follow-up. Journal of Clinical Oncology, 15, 1138–1142.
- Jasionowski, T.M., Hartung, I., Greenwood, J.H., Perkins, S.L. & Bahler, D.W. (2003) Analysis of CD10 + hairy cell leukaemia. American Journal of Clinical Oncology, 120, 228–235.
- Jehn, U., Bartl, R., Dietzfelbinger, H., Haferlach, T. & Heinemann, V. (2005) An update: 12-year follow-up of patients with hairy cell leukaemia following treatment with 2-chlorodeoxyadenosine. Leukemia, 18, 1476–1481.
- Juliusson, G., Heldal, D., Hippe, E., Hedenus, M., Malm, C., Wallman, K., Stalt, C.-M., Evensen, S.A., Albertioni, F., Tjonnfjord, G., Lenkei, R. & Liliemark, J. (1995) Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukaemia. Journal of Clinical Oncology, 13, 989–995.
- Konwalinka, G., Schirmer, M., Hilbe, W., Fend, F., Geisen, F., Knoblechner, A., Petzer, A. & Thaler, J. (1995) Minimal residual disease in hairy cell leukaemia after treatment with 2 chlorodeoxyadenosine. Blood Cells Molecules and Diseases, 21, 142–151.
- Kreitman, R.J., Stetler-Stevenson, M., Margulies, I., Noel, P., Fitzgerald, D.J., Wilson, W.H. & Pastan, I. (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukaemia. Journal of Clinical Oncology, 27, 2983–2990.
- Lauria, F., Rondelli, D., Zinzani, P.L., Bocchia, M., Marotta, G., Salvucci, M., Raspadori, D., Ventura, M.A., Birtolo, S., Forconi, F. & Tura, S. (1997) Long-lasting complete remission in patients with hairy cell leukaemia treated with 2CdA: a 5-year survey. Leukemia, 11, 629–632.
- Liliemark, J., Albertioni, F., Hassan, M. & Juliusson, G. (1998) On the bioavailablity of oral and subcutaneous 2-chloro-2’-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology, 10, 1514–1518.
- Maloisel, F., Benboubker, L., Gardembas, M., Coiffier, B., Divine, M., Sebban, C., Blanc, M., Abgrall, J.F., Lederlin, P., Harousseau, J.L., Blaise, A.M., Grosbois, B., Morice, P., Ghandour, C. & Castaigne, S. (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia in patients. A French retrospective study of 238 patients. Leukemia, 17, 45–51.
- Matutes, E., Wotherspoon, A., Brito-Babapulle, V. & Catovsky, D. (2001) The natural history and pathological features of the variant form of hairy cell leukaemia. Leukemia, 15, 184–186.
- Mercieca, J., Puga, M., Matutes, E., Moskovic, E., Salim, S. & Catovsky, D. (1994) Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leukaemia and Lymphoma, 14(Suppl. 1), 79–83.
- Mercieca, J., Matutes, E., Emmett, E., Coles, H. & Catovsky, D. (1996) 2-chlordeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. British Journal of Haematology, 93, 409–411.
- Mhawech-Fauceglia, P., Oberholzer, M., Aschenafi, S., Baur, A., Kurrer, M., Von Rohr, A., Hsu-Schmitz, S.F., Wagner, B., Delacretaz, F. & Hurwitz, N. (2006) Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukaemia. Archives of Pathology and Laboratory Medicine, 130, 374–377.
- Miranda, R.N., Briggs, R.C., Kinney, M.C., Veno, P.A., Hammer, R.D. & Cousar, J.B. (2000) Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukaemia. Modern Pathology, 13, 1308–1314.
- Mollejo, M., Algara, P., Mateo, M.S., Sanchez-Beato, M., Lloret, E., Medina, M.T. & Piris, M.A. (2002) Splenic small B cell lymphoma with predominant red pulp involvement: a diffuse variant of splenic marginal zone lymphoma. Histopathology, 40, 22–30.
- Moreau, E.J., Matutes, E., A’Hern, R.P., Morilla, A.M., Morilla, R.M., Owusu-Ankomah, K.A., Seon, B.K. & Catovsky, D. (1997) Improvement of the chronic lymphocytic leukaemia scoring system with the monoclonal antibody SN8 (CD79b). American Journal of Clinical Pathology, 108, 378–382.
- Narat, S., Gandla, J., Dogan, A. & Mehta, A. (2005) Successful treatment of hairy cell leukaemia variant with rituximab. Leukemia and Lymphoma, 46, 1229–1232.
- Nieva, J., Bethel, K. & Saven, L. (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia. Blood, 102, 810–813.
- Pileri, S., Sabattini, E., Poggi, S., Merla, E., Rompadori, D., Benfenati, D., Rondelli, D., Benni, M., Ventura, M.A. & Falini, B. (1994) Bone marrow biopsy in hairy cell leukaemia (HCL) patients, histological and immunohistological analysis of 46 cases treated with different therapies. Leukemia and Lymphoma, 14(Suppl.1), 67–71.
- Piris, M., Foucar, K., Mollejo, M., Campo, E. & Falini, B. (2008) Splenic B-cell lymphoma/leukaemia: unclassifiable. In: WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues (ed by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman), pp. 191–193. IARC Press, Lyon.
- Quach, H., Januszewicz, H. & Westerman, D. (2005) Complete remission of hairy cell leukaemia variant (HCL-v) complicated by red cell aplasia post-treatment with rituximab. Haematologica, 90(S), 26.
- Ravandi, F., Jorgensen, J.L., O’Brien, S.M., Verstovsek, S., Koller, C.A., Faderl, S., Giles, F.J., Ferrajoli, A., Wierda, W.G., Odinga, S., Huang, X., Thomas, D.A., Freireich, E.J., Jones, D., Keating, M.J. & Kantarjian, H.M. (2006) Eradication of minimal residual disease in hairy cell leukaemia. Blood, 107, 4658–4662.
- Robak, T., Jamroziak, K., Gora-Tybor, J., Blonski, J.Z., Kasznicki, M., Dwilewicz-Trojaczek, J., Wiater, E., Zdunczyk, A., Dybowicz, J., Dmoszynska, A., Wojtaszko, M., Zdziarska, B., Calbecka, M., Kostyra, A., Hellmann, A., Lewandowski, K., Stella-Holowiecka, B., Sulek, K., Gawronski, K., Skotnicki, A.B., Nowak, W., Zawilska, K., Molendowicz-Portala, L., Kloczko, J., Sokolowski, J., Warzocha, K., Seferynska, I., Ceglarek, B. & Konopka, L. (2007) Cladribine in a weekly versus daily schedule for untreated hairy cell leukemia: final report from the Polish Adult Leukaemia Group (PALG) of a prospective, randomised, multicenter trial. Blood, 109, 3672–3675.
- Sainati, L., Matutes, E., Mulligan, S.P., de Oliveira, M.P., Rani, S., Lampert, I.A. & Catovsky, D. (1990) A variant form of hairy cell leukemia resistant to alpha-interferon: clinical and phenotypic characteristics of 17 patients. Blood, 76, 157–162.
- Saven, A., Burian, C., Koziol, J.A. & Piro, L.D. (1998) Long-term follow-up of patients with hairy cell leukaemia after cladribine treatment. Blood, 92, 1918–1926.
- Saven, A., Burian, C., Adusumali, J. & Koziol, J.A. (1999) Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood, 93, 2471–2477.
- Sigal, D.S., Sharpe, R., Burian, C. & Saven, A. (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukaemia after a single course of cladribine. Blood, 115, 1893–1896.
- Sperb, R.A., von Rohr, A., Ratschiller, D., Bacchi, M., Tichelli, A., Hess, U., Cerny, T., Tobler, A. & Betticher, D.C. (1998) 2-CDA bei der Behandlung der Haarzell-Leukamie: ein Vergleich zwischen intravenoser und subkutaner Verabreichung. Schweizerische Medizinische Wochenschrift, 128, 1593–1597.
- Thomas, D.A., O’Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M.J., Giles, F.J., Cortes, J. & Kantarjian, H.M. (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood, 102, 3906–3911.
- Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M.P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V.A., Sportoletti, P., Pettirossi, V., Mannucci, R., Elliott, O., Liso, A., Ambrosetti, A., Pulsoni, A., Forconi, F., Trentin, L., Semenzato, G., Inghirami, G., Capponi, M., Di Raimondo, F., Patti, C., Arcaini, L., Musto, P., Pileri, S., Haferlach, C., Schnittger, S., Pizzolo, G., Foà, R., Farinelli, L., Haferlach, T., Pasqualucci, L., Rabadan, R. & Falini, B. (2011) BRAF mutations in hairy cell leukemia. New England Journal of Medicine, 364, 2305–2315.
- Treleaven, J., Gennery, A., Marsh, J., Norfolk, D., Page, L., Parker, A., Saran, F., Thurston, J. & Webb, D. (2011) Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. British Journal of Haematology, 152, 35–51.
- Von Rohr, A., Schmitz, S.-F.H., Tichelli, A., Hess, U., Piguet, D., Wernli, M., Frickhofen, N., Konwalinka, G., Zulian, G., Ghielmini, M., Rufener, B., Racine, C., Fey, M.F., Cerny, T., Betticher, D. & Tobler, A. (2002) Treatment of hairy cell leukaemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of Oncology, 13, 1641–1649.
- Went, P.T., Zimpfer, A., Pehrs, A., Sabatini, E., Pileri, S.A., Maurer, R., Terracciano, L., Tzankov, A., Sauter, G. & Dirnhofer, S. (2005) High specificity of combined TRAP and DBA.44 expression for hairy cell leukaemia. American Journal of Surgical Pathology, 29, 474–478.
- Zenhausern, R., Leupin, N., Hsu Schmitz, S.-F., Solenthaler, M., Tichelli, A., Heim, D., Hess, U., Leoncini, L., Bargetzi, M. & Tobler, A. (2007) A randomized study of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia. Blood, 110, 1352a.
- Zinzani, P.L., Tani, M., Marchi, E., Stefoni, V., Alinari, L., Musuraca, G., Gabriele, A., Pileri, S. & Baccarani, M. (2004) Long-term follow-up of the front-line treatment of hairy cell leukemia with 2-cholordeoxyadenosine. Haematologica, 89, 309–313.
- Zinzani, P.L., Pellegrini, C., Stefoni, V., Derenzini, E., Gandolfi, L., Broccoli, A., Argnani, L., Quirini, F., Pileri, S. & Baccarani, M. (2010) Hairy cell leukaemia: evaluation of the long-term outcome in 121 patients. Cancer, 116, 4788–4792.
Citing Literature
